Full Text View
Tabular View
No Study Results Posted
Related Studies
Topical Rapamycin to Erase Angiofibromas in TSC (Treatment)
This study is currently recruiting participants.
Verified January 2013 by The University of Texas Health Science Center, Houston
Study NCT01526356   Information provided by The University of Texas Health Science Center, Houston

First Received on February 1, 2012.   Last Updated on January 28, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Angiofibromas
Tuberous Sclerosis
Additional conditions recognized in this trial
Angiofibroma
Sclerosis
More general conditions related to this trial
Congenital Abnormalities
Genetic Diseases, Inborn
Hamartoma
Heredodegenerative Disorders, Nervous System
Malformations of Cortical Development
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue
Nervous System Diseases
Nervous System Malformations
Neurocutaneous Syndromes
Neurodegenerative Diseases
Pathologic Processes
Interventions listed in this trial
Placebo
Rapamycin
Additional drug interventions recognized in this trial
Everolimus
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
The University of Texas Health Science Center, Houston


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services